Wellgistics CEO granted 5M shares and 5M warrants

Wellgistics Health, Inc. reported that Chief Executive Officer Prashant Patel received a large equity compensation package.

Rhea-AI Filing Summary

Wellgistics Health, Inc. reported that Chief Executive Officer Prashant Patel received a large equity compensation package. On March 31, 2026, he was granted 5,000,000 shares of common stock at an indicated value of $0.20 per share, bringing his direct holdings to 9,118,247 common shares after the award. On the same date, he also received 5,000,000 warrants to purchase common stock with an exercise price of $0.0001 per share, exercisable from March 31, 2026 and expiring on March 31, 2031. Both the shares and the warrants were issued as compensation for his service and were granted in transactions exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

Insights

Equity compensation analyst

CEO receives substantial stock and warrant awards as service compensation.

Wellgistics Health granted its CEO, Prashant Patel, 5,000,000 common shares plus 5,000,000 warrants as compensation, rather than through market purchases. The warrants carry a very low exercise price of $0.0001 per share and run until March 31, 2031.

These awards increase the CEO’s direct equity stake to 9,118,247 common shares, aligning his financial outcomes with the company’s share performance. The filing states that both the shares and warrants were issued under a transaction exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933.

The overall impact for existing investors depends on the company’s total shares outstanding and future use of the warrants. Those details are not included in this excerpt, so the filing mainly documents a meaningful compensation-related increase in insider ownership.

Insider Trade Summary

Grant/Award: 10,000,000 shares

Grant/Award 2 txns

Insider Patel Prashant

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Warrant	5,000,000	$0.0001	$500.00
Grant/Award	Common Stock	5,000,000	$0.20	$1.00M

Holdings After Transaction: Warrant — 5,000,000 contracts (Direct); Common Stock — 9,118,247 shares (Direct)

Footnotes (2)

1. F1. The Issuer issued the Reporting Person 5,000,000 shares of common stock (the "Shares") as compensation for the Reporting Person's service to the Issuer. The Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
2. F2. The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock (the "Warrants") as compensation for the Reporting Person's service to the Issuer. The Warrants were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

Key Figures

Common shares granted: 5,000,000 shares Reported share value: $0.20 per share Shares held after grant: 9,118,247 shares +4 more

7 metrics

Common shares granted 5,000,000 shares Compensation grant on March 31, 2026

Reported share value $0.20 per share Value for 5,000,000-share grant

Shares held after grant 9,118,247 shares CEO direct common stock holdings post-transaction

Warrants granted 5,000,000 warrants Compensation grant on March 31, 2026

Warrant exercise price $0.0001 per share Exercise price for 5,000,000 warrants

Warrant underlying shares 5,000,000 shares Common stock issuable upon exercise

Warrant expiration March 31, 2031 End of exercise period

Key Terms

warrants, Section 4(a)(2) of the Securities Act of 1933, grant/award acquisition, Common Stock, +1 more

5 terms

warrants financial

"The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

Section 4(a)(2) of the Securities Act of 1933 regulatory

"in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Common Stock financial

"The Issuer issued the Reporting Person 5,000,000 shares of common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

expiration date financial

"expiration_date: 2031-03-31T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Wellgistics Health (WGRX) grant its CEO in this Form 4/A?

Wellgistics Health granted CEO Prashant Patel 5,000,000 common shares and 5,000,000 warrants as compensation. The awards increase his direct equity exposure and are detailed as non-market, compensation-related acquisitions.

At what prices were the Wellgistics (WGRX) CEO awards valued and exercisable?

The 5,000,000 common shares were reported at a value of $0.20 per share. The 5,000,000 warrants have an exercise price of $0.0001 per share, giving the CEO rights to acquire additional stock at a very low cost.

How many Wellgistics (WGRX) shares does the CEO hold after this transaction?

After receiving the 5,000,000-share grant, CEO Prashant Patel directly holds 9,118,247 common shares. This figure reflects his position following the reported compensation award on March 31, 2026.

When do the Wellgistics (WGRX) CEO warrants expire?

The 5,000,000 warrants issued to CEO Prashant Patel expire on March 31, 2031. They are exercisable at $0.0001 per share from March 31, 2026 until that expiration date, according to the filing details.

Were the Wellgistics (WGRX) CEO share and warrant grants registered with the SEC?

No, both the 5,000,000-share grant and 5,000,000-warrant grant were issued in transactions exempt from registration. The filing cites Section 4(a)(2) of the Securities Act of 1933 for these compensation-related awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Prashant

(Last) (First) (Middle)

C/O WELLGISTICS HEALTH, INC.

3000 BAYPORT DRIVE, SUITE 950

(Street)

TAMPA, FLORIDA 33607

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Wellgistics Health, Inc. [ WGRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/23/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		5,000,000(1)	A	$0.2	9,118,247	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant	$0.0001	03/31/2026		A		5,000,000(2)		03/31/2026	03/31/2031	Common Stock	5,000,000	$0.0001	5,000,000	D

Explanation of Responses:

1. The Issuer issued the Reporting Person 5,000,000 shares of common stock (the "Shares") as compensation for the Reporting Person's service to the Issuer. The Shares were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

2. The Issuer issued the Reporting Person 5,000,000 warrants to purchase common stock (the "Warrants") as compensation for the Reporting Person's service to the Issuer. The Warrants were issued in a transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.

	/s/ Prashant Patel	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)